Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.46 |
| ▸ | VHL | P40337 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073323 | 1.00 | CTSC (0.46) | CTSCVHLJAK2USP30MC4R | |
| SCHEMBL12422472 | 0.91 | CTSC (0.47) | CTSCJAK2USP30MC4RMC5R | |
| SCHEMBL2074846 | 0.90 | CTSC (0.48) | CTSCVHLJAK2USP30MC4R | |
| SCHEMBL2074847 | 0.90 | CTSC (0.48) | CTSCVHLJAK2USP30MC4R | |
| SCHEMBL2073451 | 0.89 | VHL (0.51) | CTSCVHLOPRM1OPRD1OPRK1 | |
| SCHEMBL7859717 | 0.89 | CTSC (0.50) | CTSCVHLJAK2USP30MC4R | |
| SCHEMBL2074469 | 0.88 | CTSC (0.61) | CTSC | |
| SCHEMBL2074471 | 0.88 | CTSC (0.61) | CTSC | |
| SCHEMBL2074854 | 0.84 | VHL (0.46) | VHLJAK2USP30MC4RMC5R | |
| SCHEMBL2074856 | 0.84 | VHL (0.46) | VHLJAK2USP30MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885VHL 4069/4885JAK2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.